HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. - Pohlmann PR; Graham D; Wu T; Ottaviano Y; Mohebtash M; Kurian S; McNamara D; Lynce F; Warren R; Dilawari A; Rao S; Mainor C; et al. (Breast cancer research and treatment, 2022)